MARKET

SEPN

SEPN

Septerna, Inc.
NASDAQ
35.95
+1.92
+5.64%
After Hours: 35.90 -0.05 -0.14% 18:42 06/12 EDT
OPEN
34.03
PREV CLOSE
34.03
HIGH
36.26
LOW
33.85
VOLUME
475.86K
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
9.85
MARKET CAP
1.62B
P/E (TTM)
-43.9971
1D
5D
1M
3M
1Y
5Y
1D
Septerna initiated with a Buy at Guggenheim
TipRanks · 2d ago
Septerna Is Maintained at Strong Buy by Raymond James
Dow Jones · 5d ago
Raymond James Maintains Strong Buy on Septerna, Raises Price Target to $53
Benzinga · 5d ago
Protego Biopharma names Jae B. Kim as chief medical officer
PUBT · 5d ago
Septerna to present preclinical data on oral hypoparathyroidism drug SEP-479 at ENDO 2026
PUBT · 5d ago
Septerna to present preclinical characterization of SEP-479
TipRanks · 5d ago
Septerna Announces First Detailed Preclinical Characterization Of SEP-479 Accepted For Oral Presentation At ENDO 2026
Benzinga · 5d ago
SEPTERNA INC <SEPN.O>: RAYMOND JAMES RAISES TARGET PRICE TO $53 FROM $47
Reuters · 5d ago
More
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

Webull offers Septerna, Inc. stock information, including NASDAQ: SEPN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SEPN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SEPN stock methods without spending real money on the virtual paper trading platform.